Advertisement
AXON vs VCYT
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Axon Enterprise (AXON) has delivered robust revenue growth, with Q1 2026 revenue rising 34% year-over-year, driven by software, services, and AI products.
- Veracyte (VCYT) reported a Q2 2026 earnings beat and raised full-year revenue guidance, though the stock experienced a sharp single-day decline following the release.
- AXON stock has shown stronger recent momentum over the past month compared to broader market benchmarks, trading near multi-week highs.
- VCYT operates in the cancer diagnostics space with expanding test portfolios, while AXON focuses on public safety technology including TASER devices and body-worn cameras.
- Sector exposure differs markedly: AXON benefits from government and law enforcement spending, whereas VCYT faces typical biotech reimbursement and adoption risks.
- Relative performance highlights AXON’s more consistent upward trend in recent market activity versus VCYT’s higher volatility.
Introduction
This comparison examines Axon Enterprise (AXON) and Veracyte (VCYT), two Nasdaq-listed companies operating in distinct sectors. AXON provides technology solutions for public safety, while VCYT develops genomic diagnostics for cancer detection and monitoring. Traders and investors seeking to understand relative performance, sector dynamics, and market positioning may find this analysis useful for evaluating opportunities across technology-enabled industrials and healthcare diagnostics. The review draws on recent financial results and observable price behavior to highlight key contrasts without offering forward-looking predictions.
Axon Enterprise (AXON) Overview and Recent Performance
Axon Enterprise develops and sells TASER conducted energy devices, body-worn cameras, and related software platforms for law enforcement and public safety agencies. In recent weeks, the stock has exhibited positive momentum amid ongoing demand for its ecosystem of hardware and recurring software services. Q1 2026 revenue reached $807 million, reflecting 34% year-over-year growth, with notable contributions from software, services, and AI-related products. Analyst coverage has included several price target increases during the period. The company is scheduled to report second-quarter results on August 5, 2026. Sentiment has been supported by strong bookings trends and product adoption, though the stock remains sensitive to broader market movements and government spending cycles.
Veracyte (VCYT) Overview and Recent Performance
Veracyte provides genomic tests that aid in the diagnosis and management of thyroid, lung, breast, and other cancers. The company reported second-quarter 2026 results on July 30, delivering an earnings per share beat and a revenue increase to approximately $150 million. Management also raised full-year 2026 revenue guidance. Despite the positive financial outcome, the stock declined sharply on the following trading day. In recent market activity, VCYT has shown elevated volatility, with the share price moving within a wide 52-week range. Broader sentiment has been influenced by clinical validation updates and reimbursement developments, typical for the diagnostics sector.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds of available strategies that cover thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions are featured in this section. Available bots span a wide range of trading styles, timeframes, and performance statistics, allowing users to review metrics such as win rates, drawdowns, and trade frequency before deployment. This transparent approach helps market participants identify automated strategies aligned with specific risk tolerances and objectives. Review the full selection on the Trending AI Robots page to explore current options.
Head-to-Head Comparison
Axon Enterprise (AXON) and Veracyte (VCYT) differ significantly in business models. AXON generates revenue from hardware sales, software subscriptions, and services tied to public safety contracts, creating relatively stable recurring revenue streams. VCYT relies on test volume growth, reimbursement rates, and clinical adoption in the diagnostics market, which can introduce greater variability. Recent momentum favors AXON, which has posted steadier gains amid analyst upgrades, while VCYT experienced a pronounced post-earnings pullback despite beating estimates. Risk factors for AXON include dependence on government budgets and competition in law enforcement technology; for VCYT, they encompass regulatory changes, payer policies, and competition from other molecular diagnostics. Sector exposure places AXON in industrials with technology overlays and VCYT in healthcare, resulting in differing correlations to economic cycles and interest rates. Market sentiment reflects these contrasts, with AXON benefiting from visible product innovation and VCYT navigating typical biotech volatility.
Tickeron AI Verdict
Based on observable factors such as revenue growth consistency, trend stability in recent market activity, and positive analyst revisions, Tickeron’s AI models currently assign a higher probabilistic preference to Axon Enterprise (AXON) over Veracyte (VCYT). AXON’s recurring revenue profile and product momentum provide a more consistent backdrop compared with VCYT’s post-earnings volatility. This assessment remains probabilistic and subject to new data releases, including AXON’s upcoming quarterly results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and VCYT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 4 bearish.
- VCYT’s TA Score: 4 bullish, 6 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а +8.20% price change this week, while VCYT (@Medical Specialties) price change was +1.94% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +11.28%. For the same industry, the average monthly price growth was +1.93%, and the average quarterly price growth was +4.98%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
Reported Earning Dates
AXON is expected to report earnings on Nov 10, 2026.
VCYT is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Aerospace & Defense (+11.28% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AXON | VCYT | AXON / VCYT | |
| Capitalization | 46.4B | 3.8B | 1,222% |
| EBITDA | 320M | 137M | 234% |
| Gain YTD | 0.542 | 12.162 | 4% |
| P/E Ratio | 237.92 | 33.73 | 705% |
| Revenue | 2.98B | 562M | 531% |
| Total Cash | 737M | 485M | 152% |
| Total Debt | 1.83B | 40.1M | 4,559% |
AXON | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 60 | 86 | |
SMR RATING 1..100 | 82 | 76 | |
PRICE GROWTH RATING 1..100 | 45 | 45 | |
P/E GROWTH RATING 1..100 | 40 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (60) in the Biotechnology industry is in the same range as AXON (90). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (60) in the Biotechnology industry is in the same range as VCYT (86). This means that AXON’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's SMR Rating (76) in the Biotechnology industry is in the same range as AXON (82). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
VCYT's Price Growth Rating (45) in the Biotechnology industry is in the same range as AXON (45). This means that VCYT’s stock grew similarly to AXON’s over the last 12 months.
AXON's P/E Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for VCYT (97). This means that AXON’s stock grew somewhat faster than VCYT’s over the last 12 months.
| AXON | VCYT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 69% | 3 days ago 80% |
| Stochastic ODDS (%) | 3 days ago 78% | 3 days ago 80% |
| Momentum ODDS (%) | 3 days ago 76% | 3 days ago 81% |
| MACD ODDS (%) | 3 days ago 76% | 5 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 76% | 3 days ago 75% |
| TrendMonth ODDS (%) | 3 days ago 70% | 3 days ago 85% |
| Advances ODDS (%) | 5 days ago 74% | 11 days ago 73% |
| Declines ODDS (%) | 11 days ago 70% | 7 days ago 79% |
| BollingerBands ODDS (%) | 3 days ago 65% | 3 days ago 69% |
| Aroon ODDS (%) | 5 days ago 80% | 3 days ago 86% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JHMM | 76.48 | 0.77 | +1.02% |
| JHancock Multifactor Mid Cap ETF | |||
| NNY | 8.31 | 0.07 | +0.85% |
| Nuveen New York Municipal Value Fund | |||
| FTRB | 24.82 | 0.03 | +0.12% |
| Federated Hermes Total Return Bond ETF | |||
| MYHA | 24.89 | 0.02 | +0.06% |
| State Street®My2027 HighYield CrptBdETF | |||
| MAYU | 34.81 | N/A | N/A |
| AllianzIM US Equity Buffer15 Unc May ETF | |||